[Experimental analysis of some cardiovascular effects of Verapamil].
In vivo and in vitro experiments showed that Verapamil dilates the coronaries, prevents coronary spasm, produces Ca++-antagonism, offers protection against myocardial necrosis, prevents arrhythmia, reduces pressure, increases the purinergic reactivity and produces inhibition of platelet aggregation. It was devoid of competitive-adrenolytic activity in the heart and vessels. A methoxy derivative of the drug (D-600) had a negative inotropic and chronotropic action and was more hypotensive than Verapamil.
D000638:Amiodarone / Q000494:pharmacology; D000818:Animals; D001001:Anura; D001145:Arrhythmias, Cardiac / Q000517:prevention & control; D001794:Blood Pressure / Q000187:drug effects; D002122:Calcium Chloride / Q000494:pharmacology; D002319:Cardiovascular System / Q000187:drug effects*; D003326:Coronary Circulation / Q000187:drug effects; D006168:Guinea Pigs; D010974:Platelet Aggregation / Q000187:drug effects; D011817:Rabbits; D051381:Rats; D013565:Sympatholytics / Q000494:pharmacology; D013566:Sympathomimetics / Q000494:pharmacology; D014700:Verapamil / Q000494:pharmacology*
D013565:Sympatholytics; D013566:Sympathomimetics; D014700:Verapamil; D002122:Calcium Chloride; D000638:Amiodarone
Analisi sperimentale di alcuni effetti cardiovascolari del Verapamil